Table 4.

Pembrolizumab

	Patient 6	Patient 7	Patient 8
Age at FD	37	61	26
MM/YY FD	11/17	03/16	04/15
History of disease/time to recurrence (months)	1. surgery, RCTX/5; 2. loc rec -> surgery/2; 3. loc rec -> surgery/3; 4. loc rec -> palliative CTX (carboplatin/paclitaxel/bevacizumab)/4; 5. loc and dist rec-> ctx with mitomycin/capecitabine/3; 6. loc PD: pembrolizumab/4; 7. loc and dist PD: best supp care	1. surgery, RT/11; 2. dist rec -> CTX (cisplatin/topotecan)/9; 3. loc PD -> CTX (paclitaxel/bevacizumab)/13; 4. loc rec -> pembrolizumab/3; 5. dist PD -> best supp care/erlotinib;	1. surgery, RTX/10; 2. loc rec -> surgery (R0)/3; 3. dist rec -> CTX (carboplatin/paclitaxel/bevacizumab)/6, DVT: end of bevacizumab, start pembrolizumab/3; 4. dist rec -> ctx vinorelbine; 5. erlotinib
Disease at indication (tumor load)	Local PD (left groin, vulva)	Local PD (left groin)	Distant metastasis (bone)
HPV status/PD-L1 status	HPV negative/PD-L1: CPS 1-5	HPV unknown/PD-L1 CPS 60	HPV negative/PD-L1 CPS unknown
Best response	PD	SD	PD
Side effects	Grade 2 CTCAE: fatigue, lymphedema	None	Grade 2 CTCAE: lymphedema, hypothyroidism
Dose reduction	No	No	No
Time to progression	4 months	3 months	3 months
Time to death from FD	Unknown	Unknown	40 month
Cause of death	Unknown	Unknown	Tumor progression

adj., adjuvant; CPS, combined positive score; CTCAE, Common Terminology Criteria for Adverse Events; HPV, human papilloma virus; loc, local; dist, distant; rec, recurrence; MM/YY FD, month/year of first diagnosis; PD1-L1, programmed cell death ligand; PD, progressive disease; RD, recurrent disease; SD, stable disease; CR, complete response; PR, partial response; FD, first diagnosis; CTX, chemotherapy; RT, radiotherapy; CRTX, chemoradiation; R0, tumor-free margins; R1, microscopic tumor residual; DVT, deep vein thrombosis; CPS, combined positive score.